Combined emphysema and cancer, from radiology to prognosis in patients treated by immunotherapy: An ancillary study of a prospective multicenter phase II IFCT-1802 SAVIMMUNE.
This cohort study evaluated INTRODUCTION: In studies evaluating the efficacy of anti-programmed cell death (ligand)1 (anti-PD-(L)1) in patients with non-small-cell lung cancer (NSCLC), smokers tend to have be. Key finding: CONCLUSION: In a single-arm cohort of PS2-3 patients with advanced NSCLC treated with 1st-line durvalumab, the presence of moderate emphysema was associated with worse overall survival.
This cohort study evaluated INTRODUCTION: In studies evaluating the efficacy of anti-programmed cell death (ligand)1 (anti-PD-(L)1) in patients with non-small-cell lung cancer (NSCLC), smokers tend to have be. Key finding: CONCLUSION: In a single-arm cohort of PS2-3 patients with advanced NSCLC treated with 1st-line durvalumab, the presence of moderate emphysema was associated with worse overall survival.
What the study was
- Study design
- Cohort study
- Category
- Treatment Innovation
- Maturity
- Validated
- Journal
- Respiratory medicine and research
Why it surfaced
High-priority cohort study in Novel therapeutics (immunotherapy, CAR-T, targeted therapy).
A plain-language summary of published research — not medical advice. Talk to a clinician about your own care.